½ÃÀ庸°í¼­
»óǰÄÚµå
1722760

»ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛ ½ÃÀå º¸°í¼­ : ¹æ¹ý, ¿ëµµ, Áö¿ªº°(2025-2033³â)

Separation Systems for Commercial Biotechnology Market Report by Methods (Modern Methods, Conventional Methods), Application (Pharmaceutical, Food and Cosmetics, Agriculture, and Others), and Region 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 144 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è »ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð´Â 2024³â 282¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â¿¡´Â 447¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â 4.98%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù.

»ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛÀº »ýÈ­ÇÐ ¹°Áú, Áø´Ü ½Ã¾à, ¹ÙÀÌ¿À ÀǾàǰÀ» Æ÷ÇÔÇÑ º¹ÀâÇÑ È¥ÇÕ¹°À̳ª ¿ë¾×¿¡¼­ »ý¹°ÇÐÀû Á¦Ç°À» Á¤Á¦ ¹× ºÐ¸®ÇÏ´Â µ¥ »ç¿ëµÇ´Â ¼Ö·ç¼ÇÀ» ¸»ÇÕ´Ï´Ù. ºÐ¸®´Â Á¦Ç°ÀÇ Á¤ÀüÇÏ, ¹Ðµµ, ÇüÅÂ, ±Ø¼º, ¿ëÇØµµ, È®»ê¼º, Èֹ߼º¿¡ µû¶ó ÀÌ·ç¾îÁý´Ï´Ù. ºÐ¸®¿¡´Â Å©·Î¸¶Åä±×·¡ÇÁ, ¸âºê·¹ÀÎ, ÇÊÅÍ, ¿ø½ÉºÐ¸®±â, ¹ÙÀÌ¿ÀĨ, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ µî ´Ù¾çÇÑ ±â±â ¹× ÀåÄ¡°¡ »ç¿ëµË´Ï´Ù. ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº ¼öÁöÀÇ »ý»ê¼ºÀ» Çâ»ó½Ã۰í, ȸ¼öÀ²À» ³ôÀ̸ç, Æó±â¹° ¹ß»ý°ú ¼¼Ã´¼ö »ç¿ëÀ» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. ±× °á°ú, ºÐ¸® ½Ã½ºÅÛÀº Á¦¾à, ½ÄÀ½·á, È­Àåǰ, ³ó¾÷ µî ´Ù¾çÇÑ »ê¾÷¿¡¼­ Æø³Ð°Ô »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

»ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛ ½ÃÀå µ¿Çâ :

¼¼°è Á¦¾à »ê¾÷ÀÇ °ý¸ñÇÒ¸¸ÇÑ ¼ºÀåÀº ½ÃÀå Àü¸ÁÀ» ¹à°Ô ÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ¸¸¼º ÁúȯÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¸ÂÃãÇü ÀǾàǰ, ¹ÙÀÌ¿À ÀǾàǰ ¹× ¼¼Æ÷ ±â¹Ý Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â »ó¾÷¿ë »ý¸í °øÇÐ¿ë ºÐ¸® ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇÃ¶ó½ºÆ½ ¹× È­ÇÐÁ¦Ç°ÀÇ »ó¾÷Àû »ý»ê¿¡ Àڱ⠺и®±â°¡ ³Î¸® äÅõǰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °£¼ÒÈ­µÈ ÀýÂ÷·Î »ý¹°ÇÐÀû À§Çè ¿ä¼Ò¸¦ Á¦Ç°º°·Î Á¦°ÅÇÏ´Â Çõ½ÅÀûÀÎ ¾÷½ºÆ®¸² ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼úÀÇ °³¹ß µî ´Ù¾çÇÑ ±â¼ú ¹ßÀüÀÌ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ¿¬±¸¼Ò ¹× ¿¬±¸±â°üµéµµ °í°¨µµ ¹× °íºÐÀÚ ºÐ¸®¸¦ À§ÇØ »õ·Î¿î °í¼º´É °¡½º Å©·Î¸¶Åä±×·¡ÇÁ, ÃÊÀÓ°è À¯Ã¼ Å©·Î¸¶Åä±×·¡ÇÁ, ¿ø½ÉºÐ¸®, Àü±â¿µµ¿ ÀåÄ¡ µîÀ» »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ, ƯÈ÷ ½ÅÈï °æÁ¦±¹ÀÇ ÇコÄɾî ÀÎÇÁ¶ó °³¼±°ú »ý¸í°øÇÐ ºÐ¾ßÀÇ ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) µîÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

  • 2024³â Àü ¼¼°è »ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð´Â?
  • 2025-2033³â »ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • »ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀ» ÁÖµµÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
  • Äڷγª19°¡ »ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛ ¼¼°è ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • »ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛ ¼¼°è ½ÃÀå¿¡¼­ÀÇ ±â¼úº° ºÐ·ù´Â?
  • ¼¼°è »ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛ ½ÃÀåÀÇ ¿ëµµº° ºÐ·ù´Â?
  • »ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀÇ ÁÖ¿ä Áö¿ªÀº?
  • »ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ Á¢±Ù
    • Åé´Ù¿î Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ »ó¾÷ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿ë ºÐ¸® ½Ã½ºÅÛ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : ¹æ¹ýº°

  • Çö´ëÀû ¹æ¹ý
    • ÁÖ¿ä ºÎ¹®
      • ¸¶ÀÌÅ©·Î¾î·¹ÀÌ
      • ·¦¿Â¾îĨ
      • Àڱ⠺и®
      • ±âŸ
  • ±âÁ¸ ¹æ¹ý
    • ÁÖ¿ä ºÎ¹®
      • Å©·Î¸¶Åä±×·¡ÇÇ
      • À¯¼¼Æ÷ºÐ¼®±â
      • ¸·¿©°ú
      • ±âŸ

Á¦7Àå ½ÃÀå ºÐ¼® : ¿ëµµº°

  • ÀǾàǰ
    • ÁÖ¿ä ºÎ¹®
      • ¹é½Å
      • ´Ü¹éÁú
      • È£¸£¸ó ¹× Àν¶¸°
      • È¿¼Ò
      • Àΰ£ Ç÷Àå ºÐȹ
      • Æ÷À¯·ù ¼¼Æ÷¹è¾ç
  • ½Äǰ ¹× È­Àåǰ
  • ³ó¾÷
  • ±âŸ

Á¦8Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå ³»¿ª : ±¹°¡º°

Á¦9Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦10Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦11Àå PorterÀÇ Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦12Àå °¡°Ý ºÐ¼®

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Agilent Technologies Inc.
    • Becton Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • Hitachi Ltd.
    • Merck KGaA
    • Pall Corporation(Danaher Corporation)
    • PerkinElmer Inc.
    • Qiagen N.V
    • Repligen Corporation
    • Sartorius AG
    • Shimadzu Corporation
    • Thermo Fisher Scientific
LSH 25.05.30

The global separation systems for commercial biotechnology market size reached USD 28.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 44.7 Billion by 2033, exhibiting a growth rate (CAGR) of 4.98% during 2025-2033.

The separation systems for commercial biotechnology refer to the solutions used for the purification and separation of biological products from complex mixtures and solutions, including biochemicals, diagnostic reagents and biopharmaceuticals. The separation is based on the electrostatic charge, density, shape, polarity, solubility, diffusivity and volatility of the product. It involves the use of various equipment and devices, such as chromatographs, membranes, filters, centrifuges, biochips and microarrays. These solutions offer improved resin productivity, higher recovery and minimal waste generation and wash water usage. As a result, separation systems find extensive applications across various industries, including pharmaceutical, food and beverage, cosmetic and agriculture.

Separation Systems for Commercial Biotechnology Market Trends:

Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. With the increasing prevalence of chronic medical ailments, there is a rising demand for personalized drugs, biopharmaceuticals and cell-based therapies, which is impacting the demand for separation systems for commercial biotechnology. Moreover, the widespread adoption of magnetic separators for the commercial production of plastics and chemicals is providing a thrust to the market growth. Additionally, various technological advancements, such as the development of innovative upstream bioprocessing technologies that facilitate in the elimination of biohazardous by-products using simplified procedures, are acting as growth-inducing factors. Biotechnological institutes and research organizations are also using novel high-performance gas and supercritical fluid chromatography, centrifugation and electrophoresis equipment for the separation of sensitive and large molecules. Other factors, including improvements in the healthcare infrastructure, especially in the developing economies, along with extensive research and development (R&D) in the field of biotechnology, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Methods:

  • Modern Methods
  • Microarray
  • Lab-on-a-Chip
  • Magnetic Separation
  • Others
  • Conventional Methods
  • Chromatography
  • Flow Cytometry
  • Membrane Filtration
  • Others

Breakup by Application:

  • Pharmaceutical
  • Vaccines
  • Proteins
  • Hormones and Insulin
  • Enzymes
  • Human Blood Plasma Fractionation
  • Mammalian Cell Cultures
  • Food and Cosmetics
  • Agriculture
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Becton Dickinson and Company, Bio-Rad Laboratories Inc., Hitachi Ltd., Merck KGaA, Pall Corporation (Danaher Corporation), PerkinElmer Inc., Qiagen N.V, Repligen Corporation, Sartorius AG, Shimadzu Corporation and Thermo Fisher Scientific.

Key Questions Answered in This Report

  • 1.What was the size of the global separation systems for commercial biotechnology market in 2024?
  • 2.What is the expected growth rate of the global separation systems for commercial biotechnology market during 2025-2033?
  • 3.What are the key factors driving the global separation systems for commercial biotechnology market?
  • 4.What has been the impact of COVID-19 on the global separation systems for commercial biotechnology market?
  • 5.What is the breakup of the global separation systems for commercial biotechnology market based on the methods?
  • 6.What is the breakup of the global separation systems for commercial biotechnology market based on the application?
  • 7.What are the key regions in the global separation systems for commercial biotechnology market?
  • 8.Who are the key players/companies in the global separation systems for commercial biotechnology market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Separation Systems for Commercial Biotechnology Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Methods

  • 6.1 Modern Methods
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Microarray
      • 6.1.2.2 Lab-on-a-Chip
      • 6.1.2.3 Magnetic Separation
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Conventional Methods
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Chromatography
      • 6.2.2.2 Flow Cytometry
      • 6.2.2.3 Membrane Filtration
      • 6.2.2.4 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Application

  • 7.1 Pharmaceutical
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Vaccines
      • 7.1.2.2 Proteins
      • 7.1.2.3 Hormones and Insulin
      • 7.1.2.4 Enzymes
      • 7.1.2.5 Human Blood Plasma Fractionation
      • 7.1.2.6 Mammalian Cell Cultures
    • 7.1.3 Market Forecast
  • 7.2 Food and Cosmetics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Agriculture
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Agilent Technologies Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Becton Dickinson and Company
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Bio-Rad Laboratories Inc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Hitachi Ltd.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Merck KGaA
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 Pall Corporation (Danaher Corporation)
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 SWOT Analysis
    • 13.3.7 PerkinElmer Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
    • 13.3.8 Qiagen N.V
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Repligen Corporation
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
    • 13.3.10 Sartorius AG
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Shimadzu Corporation
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Thermo Fisher Scientific
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦